Joi Dunbar

Author PubWeight™ 4.82^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.	Clin Cancer Res	2013	1.25
2	Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.	Urology	2011	1.06
3	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.	Leuk Lymphoma	2011	0.92
4	A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.	Clin Cancer Res	2013	0.89
5	The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.	Xenobiotica	2013	0.76